Protective immune mechanisms against pre-erythrocytic forms of Plasmodium berghei depend on the target antigen  by Bergmann-Leitner, Elke S. et al.
Trials in Vaccinology 3 (2014) 6–10Contents lists available at ScienceDirect
Trials in Vaccinology
journal homepage: www.elsevier .com/locate / t r ivacProtective immune mechanisms against pre-erythrocytic forms
of Plasmodium berghei depend on the target antigenhttp://dx.doi.org/10.1016/j.trivac.2013.11.002
1879-4378/ 2013 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author. Address: US Military Malaria Research Program, Walter
Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910,
USA. Tel.: +1 301 319 9278; fax: +1 301 319 7358.
E-mail address: Elke.S.BergmannLeitner.ctr@mail.mil (E.S. Bergmann-Leitner).
1 E.S.B.L. and Q.L. contributed equally to this work.Elke S. Bergmann-Leitner a,⇑,1, Qigui Li b,1, Diana Caridha b, Michael T. O’Neil b, Christian F. Ockenhouse a,
Mark Hickman b, Evelina Angov a
aMalaria Vaccine Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA
bDivision of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USAa r t i c l e i n f o
Article history:
Received 31 October 2013







Sporozoitea b s t r a c t
Pre-erythrocytic malaria vaccines are believed to either stop the injected sporozoites from reaching the
liver or to direct cellular immune responses towards eliminating infected hepatocytes. The present study
reveals for the ﬁrst time the anatomical sites at which these immune mechanisms act against the malaria
parasites. To determine the mechanisms leading to protection mediated by two previously characterized
vaccines against either the circumsporozoite protein (CSP) or the cell traversal protein for ookinetes and
sporozoites (CelTOS), mice were immunized and subsequently challenged by subcutaneous injection of
salivary gland sporozoites of luciferase-transgenic Plasmodium berghei parasites. The In Vivo Imaging Sys-
tem (IVIS) was used to identify the anatomical site where the vaccine-induced immune response elimi-
nates sporozoites after injection. The data demonstrate that CSP-based immunity acts at the site of
infection (skin) whereas CelTOS-based immunity is only partially efﬁcient in the skin and allows reduced
levels of liver infection that can be subsequently cleared. The results of this study challenge assumptions
regarding CSP-mediated immune mechanisms and call into question the validity of some commonly used
assays to evaluate anti-CSP immune responses. The knowledge of the mechanism and events leading to
infection or immune defense will guide supportive treatment with drugs or combination therapies and
thus accelerate the development of effective antimalarial strategies.
 2013 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Malaria vaccines that target the pre-erythrocytic stage of the
parasite life cycle have the greatest potential for inducing sterile
protection by targeting to a developmental bottleneck. The cir-
cumsporozoite protein (CSP) is the best characterized sporozoite
antigen and many different vaccine platforms have been employed
to study its prophylactic potential. Our laboratory has been suc-
cessful in inducing complete protection in inbred and outbred
mouse strains using a Plasmodium berghei CSP-based DNA vaccine
delivered by gene gun. This protection is mediated solely by
CSP-speciﬁc antibodies directed to the C-terminus of the antigen
without the requirement for cytolytic T cells [1]. The clinicallymost promising vaccine candidate based on Plasmodium falciparum
CSP, RTS,S, appears to primarily mediate protection through
CSP-speciﬁc antibodies since high titers reportedly correlate with
protection [2]. However, other vaccine platforms targeting CSP
such as heterologous prime/boost approaches using DNA and
adenoviral vectors predominantly lead to the induction of strong
cellular responses against the infected hepatocytes (reviewed in
[3]). CelTOS, on the other hand, is a relatively novel antigen iden-
tiﬁed based on its essential role during cell traversal of parasites
in the host [4]. We have previously reported on a recombinant
PfCelTOS protein-based vaccine and shown its protective potential
as a vaccine candidate in a murine model [8]. Immunity to
PfCelTOS appears unique due to its ability to mediate cross-species
protection. In the homologous P. berghei challenge model, the
recombinant PbCelTOS ortholog induced protection that was
mediated by both CelTOS-speciﬁc antibodies and CD4+ and CD8+
T cells [5]. It is likely that these antibodies interfere with the motil-
ity and the traversal of host cells by the sporozoites and that T cells
act on the intra-hepatic parasites, however, without direct access
to events occurring in vivo such models are speculative at best.
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mammalian host once they are deposited in the skin by the
mosquito. Studies have shown that only a small portion of the
sporozoites arrive in the liver and succeed in infecting hepatocytes
[5]. A signiﬁcant proportion of the sporozoites either remain in the
skin where they are capable of developing into exo-erythrocytic
forms [6], while others migrate to or are transported into draining
lymph nodes where they impact the immune response. No matter
which path the sporozoites take, they are exposed to immune cells
and molecules which result in their neutralization and lead to the
inhibition of invasion of hepatocytes. Thus, salivary gland sporozo-
ites administered by direct intravenous injections may bypass the
interactions that sporozoites have during a natural infection and
instead of taking up to 24 h to reach their target, arrive at their des-
tination within 15 min after injection [6]. Previous studies in our
laboratory compared the various challenge routes (intravenous
vs. subcutaneous injection of dissected sporozoites and compared
these to mosquito bite) and revealed that a non-natural route of
infection can introduce artifacts in the evaluation of vaccine efﬁ-
cacy [7]. Such artifacts may minimize efﬁcacy readouts of investi-
gational vaccines assessed in non-natural animal models. Recently,
the noninvasive In Vitro Imaging System (IVIS) was used to quan-
tify parasite liver stage development and vaccine efﬁcacy of whole
parasite approaches that target the induction of liver stage
immunity [8–10]. In the current study, using two pre-erythrocytic
targets delivered by their optimal vaccination platform, we eluci-
date the contribution of antibodies at the natural site of infection
using P. berghei luciferase transgenic sporozoites and the noninva-
sive in vivo imaging system with IVIS. We propose that employing
this type of in vivo real-time analysis of immune mechanisms may
directly guide future vaccine development by revealing effector
mechanisms.Materials and methods
Immunizations
Six-week old C57BL/albino (NCI, Frederick, MD) and C3He mice
(Charles River Laboratories, Wilmington, MA) were immunized
with either empty plasmid DNA, or plasmid encoding P. berghei
CSP without the GPI-anchor (designated PbCSP(-A)) or recombi-
nant P. falciparum CelTOS (PfCelTOS) protein adjuvanted in Monta-
nide ISA-720 (Seppic Inc., Fairﬁeld, NJ) using previously established
regimens [1,5]. Although both mouse strains gave us comparable
results with regards to in vivo imaging and the protection ob-
served, the data reported here are exclusively from using the
C3He mice.Sporozoite challenge
The luciferase-transgenic P. berghei parasite line was generated
at WRAIR, Division of Experimental Therapeutics and produces
luminescent oocysts and sporozoites. Laboratory-reared female
Anopheles stephensi mosquitoes (Division of Entomology, WRAIR)
were maintained after feeding on infected Swiss ICR mice at
18 C for 17–22 days. Salivary glands were dissected from malar-
ia-infected mosquitoes and sporozoites isolated as previously de-
scribed [11]. Each mouse was inoculated subcutaneously in both
inguinal regions with approximately 25,000 (C57BL/albino) or
5000 (C3He) sporozoites suspended in a total volume of 100 ll
on day 0 (50 ll suspension was injected into each inguinal area).
To ensure that inoculated sporozoites were viable following the
isolation procedure, they were stained with a vital dye containing
ﬂuorescein diacetate (50 mg/ml in acetone) and ethidium bromide
(20 lg/ml in phosphate-buffered saline; Sigma Chemical Co.,St. Louis, MO) and counted in a hemocytometer. The viability of
sporozoites ranged from 90% to 100%.
In vivo image system (IVIS)
In vivo imaging of bioluminescence activity from luciferase
expressing P. berghei infected mice was performed using an IVIS
Spectrum instrument (Perkin Elmer, Waltham, MA). Mice were
evaluated at 24, 48, and 72 h post sporozoite inoculation to deter-
mine liver- and blood-stage malaria infection. Mice received
150 mg/kg luciferin (Gold Biotechnology, St. Louis, MO) intraperi-
toneally in a volume not to exceed 150 ll. Three minutes post
luciferin administration the mice were anesthetized with inhaled
isoﬂurane. The mice were positioned ventral side up in the IVIS
on a 37 C platform. The mice continued to receive isoﬂurane
through the nose cone delivery method while IVIS imaging was
performed. The camera exposure time was set for 1 and 5 min
for the 24, 48, and 72 h time points with f-stop = 1 and large bin-
ning was selected for the image capture. Quantitative analysis
(photons) of bioluminescence emitted from the abdominal area
or regions of intensity (ROI) was performed by measuring the lumi-
nescence signal intensity using the Living Image 3.0 software
(Perkin Elmer). The ROI, whose measurements are expressed in
total ﬂux of photons, was set to measure the abdominal area at
the location of the liver for whole body imaging. Three-D biolumi-
nescent imaging tomography was performed with the software
using sequential images taken with ﬁlters ranging from 580 to
660 nm [12].
Results
In this study, we sought to identify the anatomical sites at
which immune mechanisms exhibit their effect against malaria
parasites after inducing CSP- or CelTOS-based immunity through
vaccination [11,13]. In pilot studies, we determined the suscepti-
bility of various mouse strains to luciferase-transgenic sporozoite
infection and the optimal dose of salivary sporozoites able to pro-
vide an IVIS signal at 48 h after subcutaneous challenge (data not
shown). Next, mice were immunized with either the PbCSP(-A)
plasmid delivered by gene gun [1] or recombinant PfCelTOS protein
adjuvanted in Montanide ISA 720 delivered by needle and syringe
subcutaneously [5], both model systems previously established in
our laboratory and having shown to provide sterile protection.
Mice were challenged with live sporozoites by subcutaneous injec-
tion and imaged at 24, 48 and 72 h (Fig. 1). The quantitative data
for the images in Fig. 1 are plotted as the individual kinetic
response for each mouse in Fig. 2. At 24 h post infection, some
parasites were detected at the injection site in mice immunized
with an empty vector (control plasmid) or PfCelTOS, but not in
PbCSP(-A)-vaccinated animals. By 48 h, 9/10 mice in the empty-
vector control plasmid group, 6/9 mice in the PfCelTOS vaccine
group, and 1/9 mice in the PbCSP(-A)-vaccine group, had an estab-
lished, detectable liver infection. With regards to parasite burden,
the differences in the liver ROI between the empty-vector control
group and the PbCSP(-A)-immunized mice was shown to be statis-
tically signiﬁcant (p = 0.0009, Fisher’s exact test) (Fig. 3). The differ-
ence in liver burden between the two vaccine groups was also
signiﬁcant (p = 0.017, Fisher’s exact test) indicating that mice
immunized with PfCelTOS had a higher parasite burden than mice
immunized with PbCSP(-A) plasmid at 48 h. By 72 h, no parasites
were detected in any PbCSP(-A)-vaccinated mouse, while 8/9 mice
in the PfCelTOS vaccine group had cleared their liver-stage parasite
load to levels below the detection threshold (Figs. 1 and 3). At this
time point, both vaccine groups were signiﬁcantly different from
the empty-vector control group (p < 0.003, Fisher’s exact test).













Fig. 1. Immunization with pre-erythrocytic vaccines can prevent or clear liver stage infections. Mice were immunized with either a plasmid encoding GPI-anchorless
P. berghei CSP (designated PbCSP(-A) delivered by gene gun (Panel A, B and C) or recombinant PfCelTOS protein adjuvanted in Montanide ISA-720 (Panel D, E and F) or an
empty-vector control plasmid (Panel G, H and I) or saline Montanide ISA-720 (not shown). Mice were challenged by subcutaneous injection of 5000 luciferase-transgenic
sporozoites and then imaged 24 h (Panel A, D and G), 48 h (B, E and H) and 72 h (Panel C, F and I) post challenge.
Fig. 2. Differences in the kinetic of the IVIS signal between the experimental groups. Quantitative data for PbCSP(-A) immune (Panel A), PfCelTOS immune (Panel B) and
empty-vector control plasmid immunized mice (Panel C). Lines represent changes in the ROI for each mouse in the respective groups at 24, 48 and 72 h post challenge.
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Fig. 3. Liver burden is signiﬁcantly different between the experimental groups.
Radiances (ROI) were measured at 24, 48 and 72 h. The numbers above the bars
indicate the number of mice with measurable ROI/total number of mice per group.
Some detectable radiance is observed for some animals at the site of injection at
24 h, while no detectable radiance is observed in the liver for any animal at 24 h
post infection.
E.S. Bergmann-Leitner et al. / Trials in Vaccinology 3 (2014) 6–10 9the PfCelTOS immunized mice at 72 h arose from background
luminescence from the anesthesia nose cone at extreme sensitivity
settings.Discussion
Elucidating a correlate of protection for malaria has proven to
be a formidable task severely hindering the development of efﬁca-
cious vaccines. Although correlates of protection are not necessar-
ily know for many pathogens, the search for protective immune
mechanisms against Plasmodium parasites is further complicated
by the different parasite life cycle stages and the widely diverse
immune effector mechanisms induced by the vaccine strategies
currently in evaluation. For the current study, we chose two vac-
cine platforms, and two pre-erythrocytic antigens, whose vaccina-
tion modalities are known to yield the highest level of protection in
their respective murine models. By using the IVIS imaging system
and the absolute quantiﬁcation of bioluminescence at the anatom-
ical sites where antigen-speciﬁc immunity acts to eliminate the in-
jected sporozoites, it is clear that CSP-based immunity induced by
gene gun delivery results in most sporozoites never leaving the site
of injection in the skin suggesting a strong role for circulating anti-
bodies in neutralizing these parasites.
For PfCelTOS-based immunity, detection of early liver burden
suggests that circulating antibodies alone, at least for the current
vaccine platform, are insufﬁcient to fully abrogate invasion of spor-
ozoites to the liver. By 72 h post infection, a clear reduction in liver
burden is evident since the initial in vivo bioluminescent signals
fall below the detection limit indicating a role for immune mecha-
nisms that speciﬁcally affect the intra-hepatic parasite. These re-
sults corroborate our earlier ﬁndings for PbCelTOS-speciﬁc
immunity, where both antibodies and T cells contributed to protec-
tion in a synergistic way [5]. In the current study, we cannot ex-
clude the contribution of PfCelTOS-speciﬁc antibodies inelimination of hepatic parasites since antibodies could be dragged
into newly invaded hepatocytes by binding directly to sporozoites
and interfere with the intra-hepatic parasite development. While
effector immune mechanisms affecting the intra-hepatic parasites
have also been attributed to CSP-speciﬁc T cells (reviewed in [14]),
the growing body of literature supports the speciﬁc role of CSP
antibodies – at least induced by certain vaccine platforms – in
the protection observed in preclinical models [1,15] and in clinical
settings [16,17].
The present study further elucidates our previous ﬁndings
that the effector molecules induced by two pre-erythrocytic
vaccines differ in the anatomical sites that they target. These
ﬁndings support the utility of IVIS as an investigative tool for
malaria, as well as for other pathogens, as it allows the real-
time in vivo monitoring of immune effector mechanisms in
model systems.Disclaimer
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